宫颈癌分子靶向治疗的研究进展  

Update on the molecular targeted therapy for cervical cancer

作　　者：杨莉(综述)[1,2] 程玺(审校)[1] 

机构地区：[1]复旦大学附属肿瘤医院妇瘤科,复旦大学上海医学院肿瘤学系,上海200032 [2]浙江省肿瘤医院妇瘤科

出　　处：《中国癌症杂志》2015年第1期73-80,共8页China Oncology

摘　　要：宫颈癌是世界范围内女性常见、死亡率高的恶性肿瘤。尽管其手术及放化疗治疗日趋成熟,但对晚期或转移性宫颈癌尚无满意的治疗手段。分子靶向治疗的进展为这类患者的治疗提供了新的思路。本文就针对血管内皮细胞生长因子通路、表皮生长因子受体、哺乳动物雷帕霉素靶蛋白、组蛋白去乙酰化酶、环氧化酶-2等的分子靶向类药物在宫颈癌治疗中的最新进展作一综述。Cervical cancer is one of the most common and deadliest cancers in females worldwide. Despite the treatment methods of surgery, radiotherapy and chemotherapy are maturing, the prognosis of patients with recurrent, advanced or metastatic cervical cancer remains poor. Molecular targeted therapy provides new hope for these patients. This review focuses on the advances in agents targeting vascular endothelial growth factor pathway, epidermal growth factor receptor, mammalian target of rapamycin, histone deacetylases and cyclooxygenase-2 in cervical cancer.

关 键 词：宫颈癌 分子靶向治疗 血管内皮细胞生长因子 表皮生长因子受体 哺乳动物雷帕霉素靶蛋白 组蛋白去乙酰化酶抑制剂 环氧化酶-2抑制剂 

分 类 号：R737.33[医药卫生—肿瘤]